FDA OKs First Interchangeable Ranibizumab Biosimilar

(MedPage Today) -- The FDA has approved the first interchangeable biosimilar to the ophthalmologic anti-VEGF agent ranibizumab (Lucentis), Coherus BioSciences announced.
The approval of ranibizumab-eqrn (Cimerli) covers all five current FDA-approved...